1. Home
  2. WOOF vs PHAR Comparison

WOOF vs PHAR Comparison

Compare WOOF & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Petco Health and Wellness Company Inc.

WOOF

Petco Health and Wellness Company Inc.

N/A

Current Price

$2.45

Market Cap

713.2M

ML Signal

N/A

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

N/A

Current Price

$11.97

Market Cap

816.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WOOF
PHAR
Founded
1965
1988
Country
United States
Netherlands
Employees
N/A
409
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
713.2M
816.8M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
WOOF
PHAR
Price
$2.45
$11.97
Analyst Decision
Hold
Strong Buy
Analyst Count
12
4
Target Price
$3.47
★ $35.70
AVG Volume (30 Days)
★ 3.6M
14.4K
Earning Date
12-08-2026
10-27-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 108.11
N/A
EPS
★ 0.08
N/A
Revenue
★ $5,961,467,000.00
N/A
Revenue This Year
$0.46
$2.98
Revenue Next Year
$1.23
$8.95
P/E Ratio
★ $30.88
$3,041.22
Revenue Growth
N/A
★ N/A
52 Week Low
$2.14
$9.11
52 Week High
$3.78
$21.34

Technical Indicators

Market Signals
Indicator
WOOF
PHAR
Relative Strength Index (RSI) 40.01 47.19
Support Level $2.21 $9.37
Resistance Level $2.51 $13.50
Average True Range (ATR) 0.17 0.46
MACD -0.06 -0.17
Stochastic Oscillator 2.76 9.59

Price Performance

Historical Comparison
WOOF
PHAR

About WOOF Petco Health and Wellness Company Inc.

Petco Health and Wellness Co Inc is a pet specialty retailer focused on improving the lives of pets, pet parents, and its own partners with pet care centers in approximately 50 states, the District of Columbia and Puerto Rico. The Company also offers an expanded range of consumables, supplies, and services through its website and mobile app.

About PHAR Pharming Group N.V.

Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.

Share on Social Networks: